To the content
2 . 2021

Specialized products for dietary correction of the diet of patients with non-alcoholic steatohepatitis

Abstract

Non-alcoholic steatohepatitis (NASH) is a widespread disorder associated with a number of metabolic disorders. Lifestyle modification, including diet and physical activity are currently a first-line treatment for the disease. However, there is lack of specialized products (SP) with modified carbohydrate and fat composition, containing biologically active ingredients with proven physiological effects on the liver for this disorder.

The aim of the paper is to summarize present knowledge on the biologically active ingredients with proven hepatoprotective effect and to describe the process of the development of two specialized products for clinical use in patients with NASH.

Material and methods. Food ingredients containing soy and milk proteins, soluble dietary fiber, mono- and polyunsaturated fatty acids, vitamins, minerals, soy lecithin, L-carnitine, coenzyme Q10, α-lipoic acid, betaine, flavoring and aromatic additives were used in the development of SP formulations. The mass fraction of moisture in the SP was determined by the thermo-gravimetric method on a humidity analyzer, and the water activity was determined by measuring the dew point. The nutritional and energy value of the SP was calculated using data from chemical composition tables and information from manufacturers of food ingredients.

Results and discussion. Taking into account the requirements for dietary therapy, the ingredient composition was scientifically justified and the formulations of two SP with a balanced amino acid composition were developed by using a combination of milk whey proteins, casein and soy protein isolate. The fat component included microencapsulated rapeseed oil, that is a source of mono- and polyunsaturated fatty acids (PUFAs) with the addition of ω-3 PUFAs. The carbohydrate composition was modified by eliminating mono- and disaccharides, traditionally used in sweet drinks, and adding maltodextrin in combination with sweeteners (polyols and natural sweeteners). Polydextrose, citrus pectin, inulin, and hydrolyzed guar gum are used as soluble dietary fibers. The SP included essential micronutrients (vitamins, mineral substances) and bioactive substances that have a proven physiological effect (coenzyme Q10, α-lipoic acid, L-carnitine, betaine hydrochloride, phospholipids). Technical documentation was developed and a pilot batch of SP-1 was developed for inclusion in the complex treatment of patients with NASH.

Conclusion. The formulations and technology of SP (SP-1, SP-2) for therapeutic nutrition with a given chemical composition, designed to optimize the diet therapy of patients with NASH, have been developed. SP are sources of animal and vegetable proteins, soluble dietary fiber, mono- and polyunsaturated fatty acids, including ω-3 family, vitamins, minerals and trace elements, as well as bioactive substances with antioxidant, hepatoprotective and hypolipidemic effect. The technical documentation was developed and approved, according to which a pilot batch of SP-1 was produced to assess its effectiveness as a part of complex therapy of patients with NASH.

Keywords:non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, specialized product, food ingredients, diet therapy

Funding. Research work on the preparation of the manuscript was carried out at the expense of subsidies for a state task within the framework of the Program of Fundamental Scientific Research of State Academies of Sciences for 2013-2020 (topic No. 0529-2019-0055).

Conflict of interests. The authors declare no obvious and potential conflicts of interest related to the publication of this article.

For citation: Vorobyeva V.M., Vorobyeva I.S., Morozov S.V., Sasunova A.N., Kochetkova A.A., Isakov V.A. Specialized products for dietary correction of the diet of patients with non-alcoholic steatohepatitis. Voprosy pitaniia [Problems of Nutrition]. 2021; 90 (2): 100-9. DOI: https://doi.org/10.33029/0042-8833-2021-90-2-100-109 (in Russian)

References

1. Ivashkin V.T., Drapkina O.M., Mayev I.V., Trukhmanov A.S., Blinov D.V., Pal’gova L.K., et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study result. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2015; (6): 31–41. (in Rusian)

2. Trukhan D.I. Non-alcoholic fatty liver disease: therapeutic and dietary recommendations at the stage of primary health care. Meditsinskiy sovet [Medical Council]. 2015; (17): 78–84. (in Russian)

3. Chernyak O.O., Sentsova T.B., Vorozhko I.V., Tutel’yan V.A., Gapparova K.M., Isakov V.A. Genomic, proteomic and metabolomic predictors of nonalcoholic fatty liver disease development in obese patients. Part I. Voprosy pitaniia [Problems of Nutrition]. 2015; (4): 18–24. DOI: http://doi.org/10.24411/0042-8833-2015-00030 (in Russian)

4. Ermolova T.V., Ermolov S.Yu. Nonalcoholic steatohepatitis: treatment from the standpoint of evidence-based medicine. Effektivnaya farmakoterapiya. Gastroenterologiya [Effective Pharmacotherapy. Gastroenterology]. 2011; (2): 30–4. (in Russian)

5. Masharova A.A., Danilevskaya N.N. Nonalcoholic steatohepatitis: from pathogenesis to therapy. RMZh Gastroenterologiya [ RMJ. Gastroenterology], 2013; (31): 1642–5. (in Russian)

6. Kucheryavy Yu.A., Maevskaya E.A., Akhtaeva M.L., et al. Nonalcoholic steatohepatitis and intestinal microflora: is there a potential for probiotic drugs in treatment. Meditsinskiy sovet [Medical Council]. 2013; (3): 46–51. (in Russian)

7. Kutyreva E.N., Pavlovskaya E.V., Surkov A.G., Strokova T.V., Kaganov B.S. Non-alcoholic steatohepatitis in obese children: prevalence and clinical manifestations. Voprosy dietologii [Problems of Dietology]. 2011; 1 (2): 54. (in Russian)

8. Shvarts V., Nogaller A. Non-alcoholic steatohepatitis: pathogenesis, diagnosis, treatment. Vrach [Physician]. 2011; (10): 31–5. (in Russian)

9. Andreev D.N., Maev I.V., Dicheva D.T.m et al. Diagnosis and treatment of non-alcoholic fatty liver disease: review of the 2016 European Guidelines. Consilium Medicum. 2017; 19 (8): 8–13. DOI: http://doi.org/10.26442/2075-1753_19.8.8-13 (in Russian)

10. Miller E.F. Nutrition management strategies for nonalcoholic fatty liver disease: treatment and prevention. Clin Liver Dis (Hoboken). 2020; 15 (4): 144–8. DOI: http://doi.org/10.1002/cld.918

11. Tutel’yan V.A. Chemical composition and calorific value of Russian food products: Handbook. Moscow: DeLi plyus, 2012: 284 р. (in Russian)

12. Nazarenko L.I., Petrova Yu.N., Rayhkel’son K.L., Baranovsky A.Yu. Nutritional errors in non-alcoholic fatty liver disease and ways to correct them. Eksperimental’naya i klinicheskaya gastoenterologiya [Experimental and Clinical Gastroenterology]. 2012; (2): 19–24. (in Russian)

13. Lyudinina A.Yu., Boyko E.R. Functional role of monounsaturated fatty acids in the human body. Uspekhi fiziologicheskikh nauk [Advances in the Physiological Sciences]. 2013; 44 (4): 51–64. (in Russian)

14. Qian F., Korat A.A., Malik V., et al. Metabolic effects of monounsaturated fatty acid-enriched diets compared with carbohydrate or polyunsaturated fatty acid-enriched diets in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2016; 39: 1448–57. DOI: http://doi.org/10.2337/dc16-1613

15. Yokoyama J., Someya Y., Yoshihara R., et al. Effects of high-monounsaturated fatty acid enteral formula versus high-carbohydrate enteral formula on plasma glucose concentration and insulin secretion in healthy individuals and diabetic patients. J Int Med Res. 2008; 36 (1): 137–46.

16. Albracht-Schulte K., Kalupahana N.S., Ramalingam L., et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J Nutr Biochem. 2018; 58: 1–16. DOI: http://doi.org/10.1016/j.jnutbio.2018.02.012

17. Lorente-Cebrián S., Costa A.G., Navas-Carretero S., et al. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem. 2013; 69 (3): 633–51. DOI: http://doi.org/10.1007/s13105-013-0265-4

18. Uspensky Yu.P., Balukova E.V. Non-alcoholic fatty liver disease: current perspectives of therapy. Meditsinskiy alfavit. Prakticheskaya gastroenterologiya [Medical Alphabet. Practical Gastroenterology]. 2017; 3 (27): 25–32. (in Russian)

19. Shirokova E.N. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. Gastroenterologiya [Consilium Medicum. Gastroenterology]. 2017; 19 (8-2): 74–6. DOI: http://doi.org/10.26442/2075-1753_19.8.2.74-76 (in Russian)

20. Kazyulin A.N. The possibility of early prevention of progression of non-alcoholic fatty liver disease in the practice of a clinician. Farmateka [Pharmateca]. 2017; (2): 63–70. (in Russian)

21. Tokaev E.S., Manuk'yan G.V. Protein product «Heparin». Patent RU No. 2249416 C1. Publ. 10.04.2005. Bull. No. 10. (in Russian)

22. Tutel’yan V.A., Baygarin E.K., Pogozheva A.V. Dietary fiber: hygienic characteristics and assessment of the effectiveness. Moscow: SvR ARGUS, 2012: 244 р. (in Russian)

23. Kiseleva T.L., Kochetkova A.A., Tutel’yan V.A., Sharafetdinov H.H. Cereals and foods in the diet for type 2 diabetes: monograph. Moscow: BIBLIO-GLOBUS, 2018: 690 р. DOI: http://doi.org/10.18334/9785907063297 (in Russian)

24. Namazi N., Larijani B., Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2018; 37 (2): 419–28. DOI: http://doi.org/10.1016/j.clnu.2017.06.002

25. Shilov A.M., Mel’nik M.V., Voevodina E.S. Coenzyme Q10 and vitamin E in the complex therapy of patients with CHF. Vrach [Physician]. 2011; (1): 49–52. (in Russian)

26. Zvyagintseva T.D., Glushchenko S.V. L-carnitine and oxidative stress – stress in non-alcoholic steatohepatitis. Gastroenterologiya [Gastroenterology]. 2015; 2 (103 pt II): 19–20. (in Russian)

27. Trukhan D.I. Role and place of L-carnitine in cytoprotection and correction of metabolic processes. Meditsinskiy sovet [Medical Council]. 2017; (12): 182–7. DOI: http://doi.org/10.21518/2079-701X-2017-12-182-187 (in Russian).

28. Mikelov V.A., Kayshev A.Sh., Kaysheva N.Sh., Nguen Hong Ha Thui. Betaines as medicines. Materialy V Vserossiyskoy nauchno-prakticheskoy konferentsii «Belikovskie chteniya» [Proceedings of the Fifth all-Russian Scientific-Practical conference «Belikov Readings»]. Pyatigorsk, 2017: 55–60. (in Russian)

29. Mukherjee S. Role of betaine in liver disease-worth revisiting or has the die been cast? World J Gastroenterol. 2020; 26 (38): 5745–8. DOI: http://doi.org/10.3748/wjg.v26.i38.5745

SCImago Journal & Country Rank
Scopus CiteScore
CHIEF EDITOR
CHIEF EDITOR
Viktor A. Tutelyan
Full Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Scientific Director of the Federal Research Centre of Nutrition, Biotechnology and Food Safety (Moscow, Russia)
Medicine today

21-й Всероссийский научно-практический конгресс "Современные технологии катарактальной, рефракционной и роговичной хирургии" Этой осенью российские и зарубежные офтальмологи специалисты соберутся в Москве на одном из самых значимых и масштабных профессиональных мероприятий в...

3 дня, 45 симпозиумов и рекордная явка в онлайне: как прошел 17-й Международный Междисциплинарный Конгресс по Аллергологии и Иммунологии С 23 по 25 июня в Москве на площадке конгресс-зала Radisson Slavyanskaya проходил 17-й Международный Междисциплинарный Конгресс по...

XIV Региональный научно-образовательный форум "Мать и Дитя" и Пленум Правления Российского общества акушеров-гинекологов 28-30 июня 2021 года состоится в очном формате XIV Региональный научно-образовательный форум "Мать и Дитя" и Пленум Правления Российского общества...


Journals of «GEOTAR-Media»